65,437 trials
Parkinson's Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 9; 9; 7; 5 participants
Multiple Sclerosis
Primary: Proportion of Participants Achieving a Mean Improvement of ≥ 8 Points From Baseline on the Multiple Sclerosis Walking Scale (MSWS-12) Over 24 Weeks — 0.336; 0.432…
Complications of Surgical and Medical Care: General Terms · Adverse Reaction to Drug · Sequelae of External Causes of Morbidity and Mortality
Primary: Overall Mortality — 642 participants
Atopic Dermatitis · Eczema
Primary: SCORAD Change Score — 33.34 Change Score
Migraine
Primary: Change in Pain Scores From 0-30 Minutes on a Visual Analog Scale (VAS) — 1.38; 1.22 units on a scale — p=0.674
Diabetes Mellitus
Primary: the Proportion of G4 CGM System in Agreement With the Reference Standard — 80 %20/20
Hyperparathyroidism, Secondary
Primary: Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase — 8.3; 74.0 percentage of participants — p=<0.001
Cannabis Dependence
Primary: Change From Week 0 in Cannabis Use Using Urinary CN-THCCOOH Levels at Week 8 — -334.21; -359.95 ng/mg
Acute Kidney Injury
Primary: Acute Kidney Injury — 7; 41; 9; 40 participants — p=0.377
Cigarette Smoking · Nicotine Addiction · Smoking Cessation
Primary: 7-day Point Prevalence of Smoking Abstinence — 109; 106 participants
Bowel Preparation for Colonoscopy
Primary: Chicago Bowel Preparation Scale — 33.54; 34.00; 34.67; 34.95 units on a scale — p=<0.005
Turner Syndrome
Primary: Total Brain Volume — 18.22; 19.78 percentage change
Cystic Fibrosis
Primary: Change in Sputum IL-17 Neutrophils — 55; 4 % of neutrophils positive for IL-17
Blister
Primary: Count of Participants With Blisters — 8; 47; 35 Participants
Delirium · Cognitive Impairment
Primary: Days Free of Delirium and Coma — 4; 5; 4; 5 days